Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metagenomic analysis of water column samples collected from Green Canyon 233 prior to the Deepwater Horizon incident.

Applied and environmental microbiology·2026
Same author

The chromosomal genome sequence of the buttercup lucine, <i>Anodontia alba</i> Link, 1807 (Lucinida: Lucinidae) and its associated microbial metagenome sequences.

Wellcome open research·2026
Same author

Dietary Quality and Microbiome Profiles among Rectal Cancer Patients: A Cross-Sectional Pilot Study.

Puerto Rico health sciences journal·2026
Same author

Genetic Features of the Scuticociliate Pathogen Philaster sp. Isolate FWC2 That Causes Sea Urchin Mass Mortality.

The Journal of eukaryotic microbiology·2026
Same author

Draft genome sequence of <i>Gracilimonas</i> sp. strain BCB1 isolated from the gill tissue of the lucinid bivalve <i>Stewartia floridana</i> in Pinellas County, Florida, USA.

Microbiology resource announcements·2025
Same author

Prophage regulation of <i>Shewanella fidelis</i> 3313 motility and biofilm formation with implications for gut colonization dynamics in <i>Ciona robusta</i>.

eLife·2025
Same journal

Literature-informed gene extraction and ranking for multimodal data fusion.

Briefings in bioinformatics·2026
Same journal

SA-MTP: a structure-aware framework for multifunctional therapeutic peptide annotation.

Briefings in bioinformatics·2026
Same journal

Genome assemblies and annotations are not static and need support for tracking their evolution.

Briefings in bioinformatics·2026
Same journal

A historical journey of metabolite-protein interaction discovery: from data harmonization to AI-driven prediction.

Briefings in bioinformatics·2026
Same journal

Bridging local-global transmembrane protein contexts with contrastive pretraining for alignment-free pathogenicity prediction.

Briefings in bioinformatics·2026
Same journal

Prediction of drug hypersensitivity by comprehensive modeling of HLA-peptidomes.

Briefings in bioinformatics·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Recent advances in computer-aided drug design.

Chun Meng Song1, Shen Jean Lim, Joo Chuan Tong

  • 1Institute for Infocomm Research, Connexis South Tower, Singapore 138632.

Briefings in Bioinformatics
|May 13, 2009
PubMed
Summary
This summary is machine-generated.

Computer-aided drug design (CADD) accelerates the discovery of new medicines by analyzing vast compound libraries. This overview details computational methods and data sources for efficient virtual screening and lead identification.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 23, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Computational chemistry and cheminformatics
  • Drug discovery and development
  • Bioinformatics and computational biology

Background:

  • Modern drug discovery involves screening massive compound libraries rapidly.
  • Managing and analyzing these large datasets necessitates computational approaches.
  • Computer-aided drug design (CADD) facilitates the identification of novel therapeutic agents.

Purpose of the Study:

  • To provide an overview of key data sources and computational methods in drug discovery.
  • To discuss the workflow of virtual screening campaigns for identifying new molecular entities.
  • To highlight the role of CADD in accelerating the drug development process.

Main Methods:

  • Utilizing digital repositories for drug and compound information.
  • Employing design libraries for generating and sampling diverse molecular variants.
  • Applying fold recognition for inferring protein binding sites and functions.
  • Implementing virtual screening as an in silico high-throughput screening method.

Main Results:

  • CADD methods enable efficient management and analysis of large compound libraries.
  • Virtual screening systematically evaluates chemical libraries to identify potential drug candidates.
  • Fold recognition aids in understanding protein structures and functions for drug targeting.
  • Data sources and computational tools are crucial for discovering new molecular entities.

Conclusions:

  • CADD, including virtual screening and fold recognition, is essential for modern drug discovery.
  • Effective data management and computational analysis streamline the identification of lead compounds.
  • This overview provides a roadmap for leveraging computational resources in drug design.